Dasatinib Added to Chemotherapy for Newly Diagnosed Philadelphia Chromosome Positive Leukemia (ALL)

Children's Oncology Group (COG)


Clinical Trial

Offered by: Nemours
Locations: Delaware Valley, Jacksonville, FL, Orlando, FL, Pensacola, FL

Trial Name

A Phase 2 Multi-Center Historically - Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

What is the trial about?

To look at the survival rate when a drug called dasatinib is added to standard chemotherapy.

Who can participate?

Age > 1 year and < 18

What is involved?

Length of study is approximately 7 years. Tests and procedures to be done include: Review of medical history; Complete physical exam; Assessment of performance status; Chest X-ray; ECG; ECHO); Collection of blood and urine samples; Spinal tap; DXA; minimal residual disease test; pregnancy test.

Contact Nemours Clinical Trials

Trial Name: A Phase 2 Multi-Center Historically - Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

COG#: AALL1122

Contact Information

(800) 354-5690
clinicaltrials@nemours.org